CEO Sells $2.75 Million in Shares Following Recent Insider Distribution

summarizeSummary

MoonLake Immunotherapeutics' CEO, Jorge Santos da Silva, sold 150,000 shares for approximately $2.75 million, executing a previously declared intent to sell and adding to a recent pattern of significant insider sales.

check_boxKey Events

• CEO Sells Shares

  CEO Jorge Santos da Silva disposed of 150,000 Class A ordinary shares.

• Transaction Value

  The shares were sold for a total value of approximately $2.75 million.

• Execution of Prior Intent

  This sale executes the intent declared in a Form 144 filed by the CEO on April 10, 2026.

• Part of Broader Insider Selling

  This transaction adds to a recent pattern of significant insider sales, including a $63 million sale by a major institutional investor earlier in April.

auto_awesomeAnalysis

This Form 4 reports the sale of 150,000 shares by MoonLake Immunotherapeutics' CEO, Jorge Santos da Silva, for a total of approximately $2.75 million. This transaction follows a Form 144 filed by the CEO on April 10, 2026, indicating an intent to sell these shares, and represents the execution of that intent. The sale, occurring between April 10 and April 13, is a notable disposition by a key executive. It also contributes to a broader trend of significant insider selling at the company, which has seen over $64 million in net insider sales in the last 90 days, including a substantial $63 million sale by a 10% owner and director affiliate earlier this month. This continued distribution by insiders could be perceived negatively by investors.